Navigation Links
Bioniche Pharma Acquires Duraclon(R) (clonidine hydrochloride injection) and Methadone Hydrochloride Injection USP

LAKE FOREST, Ill., Nov. 12 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced today the acquisition of Duraclon® (clonidine hydrochloride injection) and Methadone Hydrochloride Injection USP from Xanodyne Pharmaceuticals, Inc.


"Bioniche Pharma is very pleased to expand our product line with these injectable drugs," said Steve Thornton, Bioniche Pharma CEO. "These two products represent our commitment to expanding our product line with a combination of brand and generic drugs, which strengthens our position as a specialty injectables pharmaceutical company."

Duraclon®(clonidine hydrochloride injection) has a black box warning relating to risk of hemodynamic instability, especially hypotension and bradycardia in obstetrical, postpartum and peri-operative pain management. Methadone Hydrochloride Injection USP has black box warnings relating to peri-operative pain management and to conditions for distribution and use for the treatment of opioid addiction. Please refer to the Bioniche Pharma website for the complete prescribing information, including the boxed warnings, for these products.

About Bioniche Pharma:

Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets, with expertise in injectable hyaluronic acid products for use in orthopedics, rheumatology, urology, and dermatology. An internal development pipeline and an aggressive acquisition strategy for products fuel the company's growth. RoundTable Healthcare Partners, a private equity firm based in Lake Forest, Illinois, acquired Bioniche Pharma in February 2006. More information about Bioniche Pharma can be found at .

Duraclon® is a registered trademark of Astellas US LLC

SOURCE Bioniche Pharma

SOURCE Bioniche Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bioniche Pharma and Synerx Pharma Launch Fomepizole Injection
2. Bioniche Reports Fiscal 2009 Year-End Results
3. Bioniche Phase III Clinical Trial with Urocidin(TM) Given Continued Green Light by DMC
4. Bioniche Repays Revolving Credit Facility
5. Bioniche Provides a Corporate Update
6. Bioniche Pharma and Synerx Pharma Launch Melphalan Hydrochloride for Injection
7. Bioniche Represented at House of Commons Sub-Committee on Food Safety
8. Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well
9. Bioniche Reports Fiscal 2009 Third Quarter
10. Bioniche Provides a Corporate Update
11. Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM)
Post Your Comments:
(Date:6/27/2016)... Viejo, California (PRWEB) , ... June 27, 2016 , ... ... are fully customizable inside of Final Cut Pro X," said Christina Austin - CEO ... another unique style. Final Cut Pro X users can now reveal the ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/27/2016)... , ... June 27, 2016 , ... recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
Breaking Medicine Technology: